• Return to HOME


  • Home
  • Services
    • Clinical & Medical Consulting
    • Business Development
    • Pharmaceutical
    • Regulatory Affairs
    • Legal Consulting
  • Our Team
    • Michael Epstein, MD, FACG, AGAF
  • News
  • Blog
  • Contact


News

Scientific Publication: GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Patients with Genotype 1a Chronic Hepatitis C Virus Infection without Cirrhosis

November 07, 2016
Comments are off
Objective: Evaluate the safety and efficacy of OBV/PTV/r + DSV with low-dose RBV (600 mg once daily) for 12 weeks in GT1a HCV-infected patients, naïve or experienced (with pegIFN/RBV), without cirrhosis and compare with the historical SVR12 rate for 3-DAA + full-dose, weight based RBV
Continue Reading →

IBgard safe, well-tolerated in IBS patients

October 21, 2016
Comments are off
Six-month data from a real-world surveillance study shows over-the-counter IBgard is safe and well-tolerated in patients with irritable bowel syndrome, according to a press release from the manufacturer.
Continue Reading →

Patient Satisfaction with IBS Symptom Relief Using a Novel Peppermint Oil Delivery System in a Randomized Clinical Trial and in the General Population

October 21, 2016
Comments are off
A recent randomized clinical trial (RCT) of a novel peppermint oil preparation (PO-SST) demonstrated significant relief of irritable bowel syndrome (IBS) symptoms versus placebo. In addition to efficacy, patient satisfaction and post-marketing utilization are also important to assess.
Continue Reading →

INTERIM RESULTS OF REAL-WORLD DATA FROM OBSERVATIONAL STUDY DEMONSTRATE HIGH LEVELS OF PATIENT SATISFACTION AND RAPID IMPROVEMENT OF FUNCTIONAL DYSPEPSIA (PERSISTENT OR RECURRING INDIGESTION) WITH NEW NON-PRESCRIPTION FDgard®

October 17, 2016
Comments are off
Functional Dyspepsia (FD), known for its symptoms of persistent or recurring indigestion, impacts an estimated 1 in 6 adults in the U.S. Rapid symptom improvement reported by patients taking FDgard® Patients reported high overall level of satisfaction and enhanced quality of life whil
Continue Reading →

PROMINENT, PEER-REVIEWED MEDICAL JOURNAL PUBLISHES RESULTS OF A KEY STUDY DEMONSTRATING THE EFFECTIVENESS, SAFETY, AND TOLERABILITY OF THE NOVEL DELIVERY SYSTEM OF PEPPERMINT OIL IN IBgard®, A NEW MEDICAL FOOD FOR IRRITABLE BOWEL SYNDROME (IBS)

October 05, 2015
Comments are off
IBgard® demonstrated to be an effective, safe and well tolerated option to address unmet need for patients with IBS Rapid and symptomatic improvement of the most bothersome gastrointestinal symptoms at 24 hours and at four weeks First clinical trial to use patented Site Specific Targe
Continue Reading →

New formulation of IBgard improves IBS symptoms

September 21, 2015
Comments are off
IBgard, a new, more purified formulation of IBgard, an over-the-counter medical food containing a blend of L-menthol and peppermint oil, improved IBS symptoms within 4 weeks, according to data presented at the AGA’s 2015 James W. Freston Conference in Chicago. “This single-arm 2015 IB
Continue Reading →

Twenty-Four-Hour Results From a Placebo-Controlled Trial to Evaluate a Novel Peppermint Oil Delivery System, Targeting Release in the Small Intestine. Results From the U.S.-Based, 4-Week, Randomized, Placebo-Controlled, Multi-Centered IBSREST Trial

August 17, 2015
Comments are off
For IBS patients, current formulations of mint oil may cause heartburn, nausea, and anal burning because they tend to “dose-dump” in the stomach or pass all the way through the colon. However, a novel delivery system (IBgard, IM HealthScience LLC) allows solid beads of highly purified
Continue Reading →

Novel Peppermint-Oil Delivery System Reduces Symptoms of Irritable Bowel Syndrome

July 24, 2015
Comments are off
By Walter Alexander WASHINGTON, D.C. — May 20, 2015 — A novel delivery system that releases peppermint oil into the small intestine demonstrated reduction in the symptoms of irritable bowel syndrome (IBS) when compared with placebo, according to 24-hour results of Irritabl
Continue Reading →

Over-the-counter IBgard improves IBS symptoms

July 24, 2015
Comments are off
WASHINGTON — Michael Epstein, MD, senior medical advisor for IMHealthScience, discusses his presentation on IBgard, a new medical food product for the treatment of diarrhea-predominant and mixed-symptom irritable bowel syndrome. According to a press release, IBgard works by delivering
Continue Reading →
123

Key Services

  • Clinical & Medical Consulting
  • Business Development
  • Pharmaceutical
  • Regulatory Affairs
  • Legal Consulting

News & Announcements

Achieving successful bowel preparation with evening/morning split-dosing regimens of NER1006 versus trisulfate: post hoc analysis of a Phase 3 trial
Jul 25, 2017
Novel 1L Polyethylene Glycol (PEG)-Based Bowel Preparation NER1006 Achieves High Quality Bowel Cleansing with a Lower Volume than Standard 2L PEG + Ascorbate and Under 3L Total Fluid Volume Intake
Jul 25, 2017
Bowel preparation quality of NER1006 versus oral trisulfate solution as assessed by colonoscopists at site: a post hoc analysis from a randomized controlled trial
Jul 25, 2017

410-224-4887 x453

Epstein Associates, LLC
621 Ridgely Avenue, Suite 204
Annapolis, MD 21401

  • Home
  • Services
  • Our Team
  • News
  • Blog
  • Contact

© Copyright 2015, Epstein Associates, LLC
Website Design by Calvert Design Group, Inc.